FDA grants orphan-drug designation to Genoa for use of pirfenidone for treatment of I

[News]

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program - inhaled GP-101 for the treatment of IPF.

More... (http://www.news-medical.net/news/20140805/FDA-grants-orphan-drug-designation-to-Genoa-for-use-of-pirfenidone-for-treatment-of-IPF.aspx)